Zyban: Clinically Proven Aid for Smoking Cessation
Zyban
| Product dosage: 150mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | 4.68 $ | 46.80 $ (0%) | 🛒 Add to cart |
| 20 | 3.51 $ | 93.60 $ 70.20 $ (25%) | 🛒 Add to cart |
| 30 | 2.73 $ | 140.40 $ 81.90 $ (42%) | 🛒 Add to cart |
| 60 | 1.56 $ | 280.80 $ 93.60 $ (67%) | 🛒 Add to cart |
| 90 | 1.17 $ | 421.20 $ 105.30 $ (75%) | 🛒 Add to cart |
| 120 | 0.97 $ | 561.60 $ 117.00 $ (79%) | 🛒 Add to cart |
| 180 | 0.88 $ | 842.40 $ 157.95 $ (81%) | 🛒 Add to cart |
| 270 | 0.78 $ | 1263.60 $ 210.60 $ (83%) | 🛒 Add to cart |
| 360 | 0.68 $
Best per pill | 1684.80 $ 245.70 $ (85%) | 🛒 Add to cart |
Similar products
Zyban (bupropion hydrochloride) is a prescription medication specifically developed to support adults in their journey to quit smoking. Unlike nicotine replacement therapies, it functions as a non-nicotine aid that reduces withdrawal symptoms and the urge to smoke. Its efficacy is well-documented in clinical studies, making it a trusted option under medical supervision. This product card provides comprehensive, expert information for healthcare professionals and patients considering this treatment.
Features
- Active ingredient: Bupropion hydrochloride (150 mg sustained-release tablets)
- Mechanism of action: Dopamine and norepinephrine reuptake inhibitor
- Formulation: Film-coated, extended-release tablets for consistent dosing
- Packaging: Available in blister packs of 60 tablets
- Prescription status: Requires medical consultation and prescription
- Manufacturer: GlaxoSmithKline or authorized generics
Benefits
- Reduces nicotine cravings and withdrawal symptoms effectively
- Increases long-term abstinence rates compared to placebo
- Non-nicotine mechanism avoids nicotine-related side effects
- May help prevent weight gain often associated with quitting smoking
- Can be used concomitantly with behavioral support for optimal outcomes
- Sustained-release formulation supports convenient twice-daily dosing
Common use
Zyban is indicated as an aid to smoking cessation treatment in adults. It is typically prescribed as part of a comprehensive cessation program that includes behavioral support and counseling. Treatment is initiated while the patient is still smoking, with a target quit date set for the end of the first week of therapy. It is suitable for motivated individuals committed to quitting, particularly those who have struggled with other methods.
Dosage and direction
The recommended dosage is 150 mg orally once daily for the first 3 days, increased to 150 mg twice daily thereafter. Doses should be taken at least 8 hours apart to minimize the risk of insomnia. Tablets must be swallowed whole and not crushed, chewed, or divided. Treatment duration is usually 7–12 weeks; may be extended based on clinical judgment. Do not exceed 300 mg per day. Always take with or without food consistently to maintain absorption profile.
Precautions
Patients with a history of seizure disorder, eating disorders, or head trauma should use Zyban with extreme caution due to increased seizure risk. Monitor for changes in mood, behavior, or emergence of suicidal thoughts, especially in adolescents and young adults. Use cautiously in patients with hepatic or renal impairment—dose adjustment may be necessary. Avoid concomitant use with other bupropion-containing products. Not recommended during abrupt discontinuation of alcohol or sedatives.
Contraindications
Zyban is contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa due to higher seizure risk. Do not use in individuals undergoing abrupt discontinuation of alcohol or benzodiazepines. Contraindicated in those with a known hypersensitivity to bupropion or any tablet component. Not for use in patients taking monoamine oxidase inhibitors (MAOIs); allow at least 14 days between therapies. Avoid in patients with a history of epilepsy or seizure disorders.
Possible side effect
Common side effects include dry mouth, insomnia, headache, nausea, and dizziness. Less frequently, tremor, rash, sweating, or tinnitus may occur. Serious side effects can include seizures (incidence approximately 0.1%), severe allergic reactions, hypertension, and neuropsychiatric symptoms such as agitation, hostility, or suicidal ideation. Most side effects are mild to moderate and often diminish with continued use. Report any persistent or severe reactions to a healthcare provider promptly.
Drug interaction
Zyban interacts with numerous medications: it may lower seizure threshold when combined with antipsychotics, antidepressants, or tramadol. Concurrent use with MAOIs is contraindicated. It inhibits CYP2D6, potentially increasing levels of drugs like beta-blockers, SSRIs, and certain antiarrhythmics. Dose adjustments may be needed for drugs metabolized by CYP2D6. Use cautiously with levodopa or amantadine. Avoid with other dopamine-norepinephrine reuptake inhibitors.
Missed dose
If a dose is missed, skip it and resume the regular dosing schedule. Do not double the next dose to catch up, as this increases seizure risk. If consistent missed doses occur, consult a healthcare provider to assess adherence strategies. Maintaining steady blood levels is crucial for efficacy, so patients should aim for strict compliance with the prescribed regimen.
Overdose
Overdose may lead to seizures, hallucinations, tachycardia, or loss of consciousness. Symptoms can include nausea, vomiting, and drowsiness. In case of suspected overdose, seek emergency medical attention immediately. Provide supportive care; seizures may require benzodiazepines. ECG monitoring is advised due to potential QTc prolongation. There is no specific antidote; treatment is symptomatic and supportive.
Storage
Store at room temperature (15–30°C) in a dry place, away from light and moisture. Keep the blister pack in the original carton to protect from humidity. Do not freeze. Keep out of reach of children and pets. Dispose of any unused or expired medication via pharmacy take-back programs; do not flush or discard in household trash.
Disclaimer
This information is for educational purposes and does not replace professional medical advice. Always consult a healthcare provider before starting, changing, or stopping any medication. Individual results may vary; not all users will achieve smoking cessation. The manufacturer and distributors are not liable for misuse or incorrect interpretation of this data.
Reviews
Clinical trials demonstrate approximately 30–35% continuous abstinence rates at one year with Zyban, compared to 15–20% for placebo. Patients often report reduced cravings and easier transition to nonsmoking status. Some note side effects like sleep disturbances, but many find the benefits outweigh these issues when motivated to quit. Long-term user feedback emphasizes the importance of combining medication with behavioral therapy for best outcomes.